Thomas R. Walters
SAN DIEGO — Early study results have shown a meaningful decrease in IOP in glaucoma patients treated with OTX-TIC, an intracameral travoprost implant, according to a speaker.
OTX-TIC (Ocular Therapeutix) is a biodegradable, preservative-free implant of travoprost-loaded microparticles in hydrogel, which is administered via a single injection.
The prospective, multicenter, open-label clinical study is enrolling 10 patients in two dosing cohorts.
The first cohort of five patients, which received the lower dose, had an average IOP reduction in their implant-treated eye greater than in their comparator eye, which was treated with once-a-day topical travoprost, Thomas R. Walters, MD, said at the American Society of Cataract and Refractive Surgery meeting.
“We have a product here that shows extreme promise for being clinically significant in its reduction in IOP,” he said.
The implant began to show signs of biodegradation at 4 months, with the carrier hydrogel being completely absent by the seventh month.
Safety results showed three of the five subjects had adverse events, either iritis or peripheral anterior synechiae, and one subject needed topical rescue therapy. There were no clinically meaningful changes in endothelial cell counts or pachymetry from baseline, according to Walters.
“The study is ongoing,” Walters said. “We are continuing enrollment in the higher cohort, and we anticipate a reformulation of the implant that will more rapidly resorb.” – by Rebecca L. Forand
Walters TR. Evaluating the safety, tolerability and efficacy of OTX-TIC, a travoprost intracameral implant, in subjects with glaucoma. Presented at: American Society of Cataract and Refractive Surgery annual meeting; May 3-7, 2019; San Diego.
Disclosure: Walters reports he is a consultant for Ocular Therapeutix.